takeda pharmaceutical co. ltd. - TAK

TAK

Close Chg Chg %
13.81 -0.08 -0.54%

Closed Market

13.73

-0.08 (0.54%)

Volume: 960.30K

Last Updated:

Dec 6, 2024, 3:59 PM EDT

Company Overview: takeda pharmaceutical co. ltd. - TAK

TAK Key Data

Open

$13.82

Day Range

13.72 - 13.84

52 Week Range

12.58 - 15.08

Market Cap

$43.75B

Shares Outstanding

3.17B

Public Float

3.17B

Beta

0.54

Rev. Per Employee

N/A

P/E Ratio

22.59

EPS

$0.61

Yield

459.07%

Dividend

$0.33

EX-DIVIDEND DATE

Sep 30, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

1.84M

 

TAK Performance

1 Week
 
1.32%
 
1 Month
 
0.15%
 
3 Months
 
-6.82%
 
1 Year
 
-1.85%
 
5 Years
 
-31.89%
 

TAK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 14
Full Ratings ➔

About takeda pharmaceutical co. ltd. - TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

TAK At a Glance

Takeda Pharmaceutical Co., Ltd.
4-1-1 Dosho-machi
Osaka, Osaka 540-8645
Phone 81-6-6204-2111 Revenue 29.49B
Industry Pharmaceuticals: Major Net Income 996.30M
Sector Health Technology Employees 49,281
Fiscal Year-end 03 / 2025
View SEC Filings

TAK Valuation

P/E Current 22.377
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 43.624
Price to Sales Ratio 1.489
Price to Book Ratio 0.907
Price to Cash Flow Ratio 9.914
Enterprise Value to EBITDA 8.848
Enterprise Value to Sales 2.611
Total Debt to Enterprise Value 0.469

TAK Efficiency

Revenue/Employee 598,326.486
Income Per Employee 20,216.678
Receivables Turnover 6.397
Total Asset Turnover 0.288

TAK Liquidity

Current Ratio 1.106
Quick Ratio 0.583
Cash Ratio 0.198

TAK Profitability

Gross Margin 54.527
Operating Margin 12.433
Pretax Margin 1.086
Net Margin 3.379
Return on Assets 0.973
Return on Equity 2.08
Return on Total Capital 1.184
Return on Invested Capital 1.226

TAK Capital Structure

Total Debt to Total Equity 75.116
Total Debt to Total Capital 42.895
Total Debt to Total Assets 36.16
Long-Term Debt to Equity 69.156
Long-Term Debt to Total Capital 39.492
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Takeda Pharmaceutical Co. Ltd. - TAK

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
30.15B 31.76B 29.72B 29.49B
Sales Growth
-0.39% +5.34% -6.43% -0.78%
Cost of Goods Sold (COGS) incl D&A
13.20B 13.57B 12.76B 13.41B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.28B 5.19B 4.90B 5.03B
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
-4.47% +2.87% -6.00% +5.08%
Gross Income
16.96B 18.19B 16.96B 16.08B
Gross Income Growth
+3.03% +7.25% -6.74% -5.20%
Gross Profit Margin
+56.24% +57.26% +57.07% +54.53%
2021 2022 2023 2024 5-year trend
SG&A Expense
12.55B 12.57B 12.03B 12.34B
Research & Development
4.30B 4.68B 4.67B 5.05B
Other SG&A
8.26B 7.89B 7.36B 7.29B
SGA Growth
-6.29% +0.13% -4.27% +2.52%
Other Operating Expense
183.73M 184.41M 69.85M 76.43M
Unusual Expense
380.67M 1.45B 760.91M 1.51B
EBIT after Unusual Expense
3.84B 3.98B 4.10B 2.16B
Non Operating Income/Expense
1.01B 110.81M (258.72M) (1.15B)
Non-Operating Interest Income
16.79M 40.86M 40.64M 78.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.39B 1.26B 1.01B 1.06B
Interest Expense Growth
-4.51% -9.44% -20.20% +5.56%
Gross Interest Expense
1.39B 1.26B 1.01B 1.06B
Interest Capitalized
- - - -
-
Pretax Income
3.45B 2.83B 2.83B 320.31M
Pretax Income Growth
+717.85% -18.05% +0.08% -88.69%
Pretax Margin
+11.45% +8.91% +9.53% +1.09%
Income Tax
(93.69M) 644.33M 428.37M (632.12M)
Income Tax - Current - Domestic
1.24B 1.86B 1.82B 742.37M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(1.34B) (1.21B) (1.39B) (1.37B)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.55B 2.05B 2.34B 997.20M
Minority Interest Expense
1.57M 952.19K 154.96K 899.02K
Net Income
3.55B 2.05B 2.34B 996.30M
Net Income Growth
+771.28% -42.25% +14.26% -57.41%
Net Margin Growth
+11.76% +6.45% +7.87% +3.38%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
3.55B 2.05B 2.34B 996.30M
Preferred Dividends
- - - -
-
Net Income Available to Common
3.55B 2.05B 2.34B 996.30M
EPS (Basic)
1.1349 0.6547 0.7537 0.3184
EPS (Basic) Growth
+768.32% -42.31% +15.12% -57.76%
Basic Shares Outstanding
3.12B 3.13B 3.10B 3.13B
EPS (Diluted)
1.1265 0.649 0.7451 0.3152
EPS (Diluted) Growth
+767.21% -42.39% +14.81% -57.70%
Diluted Shares Outstanding
3.15B 3.15B 3.14B 3.16B
EBITDA
9.50B 10.62B 9.76B 8.70B
EBITDA Growth
+16.51% +11.84% -8.11% -10.86%
EBITDA Margin
+31.50% +33.44% +32.84% +29.51%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 15.319
Number of Ratings 14 Current Quarters Estimate 0.101
FY Report Date 12 / 2024 Current Year's Estimate 0.263
Last Quarter’s Earnings 0.19 Median PE on CY Estimate N/A
Year Ago Earnings 0.295 Next Fiscal Year Estimate 0.456
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 9 10
Mean Estimate 0.10 -0.14 0.26 0.46
High Estimates 0.11 -0.06 0.43 0.75
Low Estimate 0.09 -0.21 0.17 0.19
Coefficient of Variance 19.04 -78.35 30.67 42.07

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 7
OVERWEIGHT 0 0 2
HOLD 9 9 8
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Takeda Pharmaceutical Co. Ltd. in the News